Trial · NCT01639001
Results by group292
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 292
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Based on IRR by Treatment Arm | Crizotinib | 11.1 | 95% Confidence Interval 8.3 to 12.6 | Months | |
| Progression-Free Survival (PFS) Based on IRR by Treatment Arm | Chemotherapy | 6.8 | 95% Confidence Interval 5.7 to 7.0 | Months | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR | Crizotinib | 87.5 | 95% Confidence Interval 79.6 to 93.2 | Percentage of participants | |
| Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR | Chemotherapy | 45.6 | 95% Confidence Interval 35.8 to 55.7 | Percentage of participants | |
| Overall Survival (OS) | Crizotinib | 33.7 | 95% Confidence Interval 26.5 to 42.5 | Months | |
| Overall Survival (OS) | Chemotherapy | 32.9 | 95% Confidence Interval 23.9 to 43.1 | Months | |
| Percentage of Participants With Disease Control at 12 Weeks Based on IRR | Crizotinib | 82.7 | 95% Confidence Interval 74.0 to 89.4 | Percentage of participants | |
| Percentage of Participants With Disease Control at 12 Weeks Based on IRR | Chemotherapy | 73.8 | 95% Confidence Interval 64.2 to 82.0 | Percentage of participants | |
| Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months | Crizotinib | Up to 1 year | 79.3 | 95% Confidence Interval 70.0 to 86.0 | Percentage of paricipants |
| Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months | Chemotherapy | Up to 1 year | 79.5 | 95% Confidence Interval 70.0 to 86.3 | Percentage of paricipants |
| Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months | Crizotinib | Up to 18 months | 71.2 | 95% Confidence Interval 61.2 to 79.0 | Percentage of paricipants |
| Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months | Chemotherapy | Up to 18 months | 72.1 | 95% Confidence Interval 62.0 to 79.9 | Percentage of paricipants |
| Duration of Response (DR) Based on IRR | Crizotinib | 44.4 | 95% Confidence Interval 35.9 to 60.0 | Weeks | |
| Duration of Response (DR) Based on IRR | Chemotherapy | 18.1 | 95% Confidence Interval 16.7 to 19.9 | Weeks | |
| Time to Tumor Response (TTR) Based on IRR | Crizotinib | 6.3 | Full Range 5.1 to 24.9 | Weeks | |
| Time to Tumor Response (TTR) Based on IRR | Chemotherapy | 12.1 | Full Range 5.7 to 36.1 | Weeks | |
| Time to Progression (TTP) Based on IRR | Crizotinib | 12.0 | 95% Confidence Interval 8.4 to 15.4 | Months | |
| Time to Progression (TTP) Based on IRR | Chemotherapy | 6.9 | 95% Confidence Interval 5.7 to 7.1 | Months | |
| Intracranial Time to Progression (IC-TTP) Based on IRR | Crizotinib | NA | 95% Confidence Interval 20.8 to NA | Months | |
| Intracranial Time to Progression (IC-TTP) Based on IRR | Chemotherapy | 16.0 | 95% Confidence Interval 12.6 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01639001/results